Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 7, 1998

View Archived Issues

Imutec reports positive phase I/II results for Virulizin

Maracenines: isolation and characterization of new antibacterial agents

MMP inhibitors in early development at British Biotech

Antiadhesion agents prepared and evaluated at Hoechst

First small-molecule G-CSF mimic synthesized by SB-Ligand team

PJ-1, an antiplatelet compound with a dual mechanism of action

Positive clinical trial results reported for HTF-919

Substituted pyrimidines from Amgen inhibit cytokine production

Bradykinin B2 antagonists in the pipeline at Fournier

Maruishi licenses rights to Chirocaine in Japan

Broad-spectrum parenteral cephalosporin launched this week in Japan

Zeneca acquires Australian pharmaceuticals business

EMD-122946, a potent and orally active ETA antagonist looks promising in preclinical studies

L-375052, a potent thrombin inhibitor with improved pharmacokinetics

Isoxazoline- and isoxazole-containing factor Xa inhibitors prepared by DuPont

Candidate oral fibrinogen receptor antagonist presented by Uriach at ACS meeting

Potent, orally active, second-generation neuroimmunophilin from Guilford

Invicorp trial results highlighted at recent congress

DMP-695: ACS debut for new, orally active CRF1 antagonist

MDX-CD4 development progresses, triggering milestone payment from Eisai

Lilly and Synaptic enter late-stage trials with antimigraine agent

Oral osteoporosis product developed by Lilly and Emisphere heads for clinical trials

Efficacy and safety of sublingual apomorphine in treatment of MED

Hyaluronic acid oligosaccharides inhibit tumor metastasis

Bayer, Fournier to copromote statin in some EU countries

FDA indicates approvability of DepoCyt for neoplastic meningitis from lymphomas

Enbrel efficacy demonstrated in juvenile RA patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...